Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Decreases By 61.9%

Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) was the recipient of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totaling 10,835 shares, a decrease of 61.9% from the November 30th total of 28,413 shares. Based on an average daily volume of 7,085 shares, the short-interest ratio is presently 1.5 days. Based on an average daily volume of 7,085 shares, the short-interest ratio is presently 1.5 days.

Algernon Pharmaceuticals Trading Up 1.6%

Shares of AGNPF opened at $0.06 on Friday. The business’s fifty day moving average is $0.06 and its 200 day moving average is $0.05. Algernon Pharmaceuticals has a 12-month low of $0.04 and a 12-month high of $0.09.

Algernon Pharmaceuticals Company Profile

Algernon Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.

The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF).